University of Pennsylvania School of MedicineJun 20 2024
Many oncologists might find it surprising to combine a JAK inhibitor with immunotherapy since the focus has typically been on creating a strong inflammatory response for effective anti-PD1 treatment. However, there's a growing understanding that chronic inflammation, especially chronic interferon, can be harmful.
The study's co-first authors were Divij Mathew, PhD, a postdoctoral researcher in the Wherry Lab, and Melina Marmarelis, MD, an assistant professor of Medicine at the University of Pennsylvania Perelman School of Medicine and principal investigator of the clinical trial. Other study co-authors include Caitlin Foley, MD, PhD, a former medicine fellow in the Minn Lab, and Joshua Bauml, MD, former assistant professor of Medicine and co-principal investigator of the clinical trial.